BCRX · BioCryst Pharmaceuticals, Inc.
$9.38
-1.37% last session
End-of-day data · updated 2026-07-25
Market cap
$2B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
9.3
Dividend yield
—
Beta
0.54
Avg volume
5M
Employees
0K
2D change
-0.43%
5D change
2.52%
10D change
-0.74%
30D change
-5.66%
60D change
10.27%
MTD change
-3.21%
YTD change
19.74%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BCRX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-07
Latest call per bank · past 12 months
RBC Capital
Outperform$14.00
+49.3% vs priceBarclays
Equal-Weight$9.00
-4.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-07 | RBC Capital | Maintains | Outperform | $13.00 → $14.00 |
| 2026-06-30 | HC Wainwright & Co. | Maintains | Buy | $32.00 |
| 2026-06-30 | Cantor Fitzgerald | Maintains | Overweight | $27.00 → $29.00 |
| 2026-05-07 | Citizens | Maintains | Market Outperform | $25.00 → $28.00 |
| 2026-05-07 | Wedbush | Maintains | Outperform | $22.00 → $21.00 |
| 2026-05-06 | Needham | Maintains | Buy | $18.00 → $16.00 |
| 2026-01-30 | RBC Capital | Maintains | Outperform | $14.00 → $13.00 |
| 2025-12-15 | HC Wainwright & Co. | Maintains | Buy | $30.00 → $32.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 47 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.6% above the 50-day MA ($9.23).
- Price vs 200-day MA: Trading 14.9% above the 200-day MA ($8.16).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.13) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($6.24) and high ($11.11).
BCRX Price Chart
Loading chart for BCRX…
Fundamentals
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$55B 10.6% YTD
HLN
Haleon plc
$43B -2.0% YTD
TEVA
Teva Pharmaceutical Industries
$36B -1.3% YTD
ZTS
Zoetis Inc.
$32B -39.2% YTD
UTHR
United Therapeutics Corporation
$26B 8.5% YTD
VTRS
Viatris Inc.
$20B 40.7% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 23.9% YTD
ELAN
Elanco Animal Health Incorporat
$12B 10.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.